Production (Stage)
Arbutus Biopharma Corporation
ABUS
$3.22
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 12.07% | 17.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.07% | 17.55% | |||
| Cost of Revenue | 1.69% | -38.28% | |||
| Gross Profit | 0.57% | 44.05% | |||
| SG&A Expenses | -30.83% | 85.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.22% | -8.34% | |||
| Operating Income | 16.86% | 10.32% | |||
| Income Before Tax | -95.71% | 36.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -95.71% | 36.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -95.71% | 36.44% | |||
| EBIT | 16.86% | 10.32% | |||
| EBITDA | 17.20% | 10.50% | |||
| EPS Basic | -94.55% | 36.63% | |||
| Normalized Basic EPS | 17.45% | 9.79% | |||
| EPS Diluted | -85.57% | 33.56% | |||
| Normalized Diluted EPS | 17.45% | 9.79% | |||
| Average Basic Shares Outstanding | 0.53% | 0.37% | |||
| Average Diluted Shares Outstanding | 0.53% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||